Novartis races into clinic with swine flu vax

Novartis has begun testing a new swine flu vaccine in a clinical trial, but says it expects to get the jab on the market long before the study winds up a year from now. Sanofi-Pasteur, meanwhile, expects to launch human trials in a matter of days. Novartis is planning to use egg-based production methods for half of its new flu vaccine, with cell-based technology used to manufacture the other half. And it also expects to test vaccines with and without an adjuvant. While the WHO has recommended the use of adjuvants to extend the reach of global supplies, the U.S. has yet to follow Europe's lead on the use of a booster--though that may change this fall. Report